Abstracts 2022
DOI: 10.1136/gutjnl-2022-basl.27
|View full text |Cite
|
Sign up to set email alerts
|

OP14 Early Access to Medicines Scheme for pemigatinib to treat adults with locally advanced or metastatic, relapsed/refractory cholangiocarcinoma with fibroblast growth factor receptor 2 fusion or rearrangement

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles